

Microfluidic production of monodisperse phase-change nanodroplets for enabling ultrasound imaging and therapy: In vitro and in vivo assessment

Samir Cherkaoui

CRS 2022 Annual Meeting

July 11-15 2022, Montreal, Canada



LIFE FROM INSIDE




Gas filled microbubbles for CEUS

SONOVue®
Sulphur Hexafluoride




BRACCO
LIFE FROM INSIDE

Microbubbles structure



- Gas stabilized by a lipid shell
- Diameter < 8 μm (smaller than RBC)



- Highly compressible
- Oscillate in response to the incoming ultrasound wave




*Nico de Jong et al., Thorax Center,
Erasmus University Rotterdam*



CEUS: Contrast Enhanced UltraSound




Monodisperse vs Polydisperse MBs




$$f_0 = \frac{1}{2\pi} \sqrt{\frac{3\kappa P_0}{\rho R_0^2}}$$



Segers et al. 2017
Helbert et al. 2020




MICROFLUIDIC DEVICE



Shell composition :
DSPC/DPPE-PEG5000 (9/1) @50°C
Production rate :
200-500x10⁶ MSB/mL & 9 mL of product/h

$$d_b \propto D \left(\frac{Q_g}{Q_l} \right)^{0.4}$$




- **Monodisperse microbubbles** as optimal **cavitation nucleus** for US applications
- **15-40 times higher acoustic efficiency** compared to regular polydisperse MB



NDs: New frontiers beyond vessels

Nano/micron-sized US responsive agents




⚠ Ultrasound Contrast Agent - MBs

- ❑ Short in vivo circulation time due to gas core
- ❑ Remain only in the blood circulation due to large size

Main advantages over microbubbles

- **Extravasation and tumor accumulation** via either EPR* effect (NB/ND)
- Improved **stability** and **longer residence time** (ND)
- **Selectively activated**, both spatially & temporally (ND)
→ Acoustic Droplet Vaporization Shift “On/Off”




* EPR Enhanced Permeability Retention



Nanodroplets production

Microbubbles condensation procedure


- Use of **highly volatile** compounds : C_4F_{10} (b.p. $-2^{\circ}C$) or C_3F_8 (b.p. $-36^{\circ}C$)
- Ability to **modify and manipulate** microbubbles prior to condensation
- NDs size/distribution depends on **initial MBs**
- **Low NDs concentration**



Microfluidic technology (NanoAssemblR benchtop)

Organic phase :
- Shell molecules
- PFC in EtOH

Aqueous phase



NanoAssembly™
Instrument



Microfluidic
cartridge

- ◆ **Process parameters**
 - Total Flow Rate (TFR)
 - Flow Rate Ratio (FRR)
- ◆ **Formulation parameters**
 - Encapsulating shell
 - Perfluorocarbon core

➔ **Targeted size**
< 400 nm & PDI ≤ 0.2



➔ **Formulation of various types of PFC nanodroplets in terms of composition and size**



PFC-NDs characterization


PHYSICOCHEMICAL

- ✓ Size
- ✓ Polydispersity (PDI)
- ✓ Zeta Potential
- ✓ Concentration
- ✓ Stability (storage @ 4°C)





ACOUSTICAL


Home-made ADV setup



- An ultrasound probe (6 MHz) is used to activate and image the NDs vaporization for a real-time imaging
- The acoustic pressure increase every 10 seconds until the observation of the nanodroplets vaporization into MBs
- The VueBox™ software is used to measure the echopower values from B-mode imaging videos and thus to determine the ADV threshold



Increase of the echogenicity with the MBs production



VueBox™
- Matlab fit

Melich et al. 2020



Results with Perfluoropentane NDs

Shell nature effect on NDs characteristics and ADV threshold




PHYSICOCHEMICAL

ACOUSTICAL

LIPIDS

DPPC:DSPEG-PEG2000




Size	286 ± 6 nm
Polydispersity index	PDI: 0.294
Zeta potential	-32.2 ± 2.4 mV



FLUORINATED SURFACTANTS

Zonyl FSO




Size	287 ± 2 nm
Polydispersity index	PDI: 0.078
Zeta potential	-10.0 ± 2.2 mV





POLYMERS

PLGA-PVA


Size	291 ± 14 nm
Polydispersity index	PDI: 0.163
Zeta potential	-13.9 ± 2.6 mV




In vivo behavior of F-NDs



C_4F_{10} Assay




- IV injection in the tail vein of rat (n=5) : 8.0×10^9 Particles/kg
- Blood samples collected in heparinized tubes from a catheter inserted in the left carotid artery




- ✓ Distribution half-life ($T_{\alpha} \frac{1}{2}$) corresponding to **3.1-fold** that of MBs of similar composition¹

1. Schneider et al., 2011

Fluorescence detection



- IV injection in the tail vein of rat (n=5) : 8.0×10^9 Particles/kg
- Blood samples collected in heparinized tubes from a catheter inserted in the left carotid artery




- ✓ $T_{\alpha} \frac{1}{2}$ has shown a longer time of **24 min**
- ✓ Due to the **circulating remanent fluorescence** into the blood from F-NDs but also from F-liposomal and other F-lipidic structures


Vaporization detection



- IV injection in the tail vein of rat (n=5) : 8.0×10^9 Particles/kg
- L11-4v probe – Verasonics
- Positioned **longitudinally** on the **abdominal vein**
- 6 seconds** of vaporization for different time intervals until 60 min



- ✓ **Bi-phasic decay**
- ✓ In vivo : **$T_{\alpha} \frac{1}{2} = 9$ min**



Take home message

- ❑ Microfluidic technology : rapid, robust, tunable and scalable platform for designing and **manufacturing monodisperse PFC-NDs**
- ❑ Custom-made **acoustic set-up**: powerful and versatile tool for **ADV threshold determination** and **real-time monitoring of NDs** (Conversion to gaseous microbubbles)
- ❑ F-ND **in vivo circulation behavior** was addressed using **3 experimental procedures**
 - ✓ **Longer circulation time** of lipid-coated NDs confirmed
 - ✓ F-NDs **accumulation in organs** (mainly liver and spleen) was observed by the fluorescence evaluation and confirmed by the vaporization
- ❑ New opportunities for **US extravascular theranostic** applications



Acknowledgements

Bracco Suisse, Geneva site, Switzerland


Thank you !



Romain Melich
Philippe
Bussat
Anne Lassus
David Lazarus
Alexis Vivien
Emmanuel
Gaud
Patricia Emmel
Isabelle Tardy
Thierry
Bettinger



Tim Segers
Guillaume
Lajoinie
Michel
Versluis



samir.cherkaoui@bracco.com

www.linkedin.com/in/samir-cherkaoui-7380b519